Download PDF
Arzneimittelforschung 2011; 61(2): 104-111
DOI: 10.1055/s-0031-1296175
Anti-osteoporotic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis

Johann D Ringe
1   West-German Osteoporosis Center (WOC) and Medical Clinic 4, Klinikum Leverkusen, University of Cologne, Germany
,
Erich Schacht
2   Zürich Osteoporosis Research Group (ZORG), Zollikerberg, Switzerland
,
Laurent Dukas
3   Department of Medicine, Acute Geriatric University Clinic, Basel, Switzerland
,
Ze-ev Mazor
4   Bone Metabolism Unit, Teva Pharmaceutical Industries Ltd., Jerusalem, Israel
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2011 (online)

    Permissions and Reprints

Abstract

This is a preplanned subgroup analysis on 318 patients with glucocorticoid-induced osteoporosis (GIOP) from an open, prospective, multi-centered, uncontrolled study on a large cohort of elderly patients with a high risk of falls and fractures. The entire group of 2579 patients was recruited by 818 practicing physicians and treated for three months with a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1 μg alfacalcidol (CAS 41294-56-8) (Tevabone®). The average age of the GIOP patients was 71 years and the mean body mass index 26.7 kg/m2. 58% had a diagnosis of increased risk of falls, prevalent vertebral and non-vertebral fractures were documented in 70% and 65% of the patients, respectively, and a creatinine clearance (CrCl) below 65 ml/min was documented in 55%. Main outcome parameters were the Chair Rising Test (CRT), Timed Up and Go Test (TUG), back pain and safety at onset and after 3 months. In addition, an evaluation of the package design was done at the end of the study.

The percentage of patients able to perform the CRT within 10 sec increased from 21.1% to 39.4% after 3 months (increase 87%, p < 0.0001), while successful performance of TUG within 10 sec increased by 84% (p < 0.0001) from 23.1% at onset to 42.4% after 3 months.

The mean time required to perform the CRT decreased after 3 months from an average of 15.92 to 14.02 sec (p = 0.0025) (difference of 1.9 sec) and for the TUG the mean time decreased from 16.86 sec to 14.64 sec (p = 0.0056) (difference of 2.2 sec).

Mean back pain measured by a 0–10 visual analogue scale decreased significantly by 43% from 6.0 to 3.4 (p < 0.0001). Throughout the study 23 adverse events (AE) were reported in 11 of the 318 GIOP patients (incidence: 3.5%). There were no patients who experienced serious AE. Patients using the new combined regimen of alfacalcidol plus alendronate for treating GIOP achieved significant improvements in CRT, TUG and back pain already after 3 months, with a high safety profile and good compliance. This may contribute to the previously shown significant effect on reducing falls and fractures with the same regimen during a controlled long-term trial in primary osteoporosis.

Key words

Alendronate - Alfacalcidol - Back pain - Balance - Glucocorticoid-induced osteoporosis - Muscle
 

  • References

  • 1 Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA et al Low BMD is less predictive than reported falls for limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone. 2005; 36: 387-97
    CrossrefPubMedGoogle Scholar
  • 2 Runge M, Schacht E. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Muscoloskelet Neuronal Interact. 2005; 5 (2) 127-34
    PubMedGoogle Scholar
  • 3 Järvinen TLN, Sievanen H, Khan KM, Heinonen A, Kannis P. Shifting the focus in fracture prevention from osteoporosis to falls. Br Med J. 2008; 336: 124-6
    CrossrefPubMedGoogle Scholar
  • 4 Sambrook PN, Birmingham J, Kelly PJ, Kempler S, Pocock NA, Eisman JA. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin. N Engl J Med. 1993; 328: 1747-52
    CrossrefPubMedGoogle Scholar
  • 5 Ringe JD, Cöster A, Meng T, Schacht E, Umbach R. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int. 1999; 63: 337-40
    PubMedGoogle Scholar
  • 6 Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkès CJ et al Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int. 1999; 9: 75-81
    CrossrefPubMedGoogle Scholar
  • 7 Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J et al Prevention of corticosteroid-induced osteoporosis by alfacalcidol. ZRheumatol. 2000; 59 (Suppl 1) 48-52
    PubMedGoogle Scholar
  • 8 Sambrook PN, Henderson NK, Keogh A, Macdonald P, Glanville A, Spratt P et al Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2000; 15: 1818-24
    CrossrefPubMedGoogle Scholar
  • 9 Saag KG for the Glucocorticoid-induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998; 339: 292-9
    CrossrefPubMedGoogle Scholar
  • 10 Cohen S, Levy RM, Keller M, Boling E, Emkey R, Greenwald M et al Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42: 2309-18
    CrossrefPubMedGoogle Scholar
  • 11 Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB et al Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004; 350: 767-76
    CrossrefPubMedGoogle Scholar
  • 12 Schacht E, Ringe JD. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study. Arzneimittelforschung. 2011; 61 (1) 40-54
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Zhu K, Devine A, Prince R. Neuromuscular function and bone density as independent predictors of fracture in older women: a 10-year longitudinal study. Bone. 2008; 43: S26-S37
    PubMedGoogle Scholar
  • 14 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1) 31-41
    Google Scholar
  • 15 Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990; 13 (4) 227-236
    CrossrefPubMedGoogle Scholar
  • 16 American Geriatrics Society British Geriatrics Society and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc. 2001; 49: 664-72
    CrossrefPubMedGoogle Scholar
  • 17 DVO Leitlinie. Osteoporose bei postmenopausalen Frauen. DVO-Leitlinie 2003 (serial online); (46 screens). Available from: http://www.lutherhaus.de/osteo.leitlinien-dvo/ [German]
    PubMed
  • 18 Podsialdo D, Richardson S. The Timed Up and Go Test: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991; 39 (2) 142-8
    PubMedGoogle Scholar
  • 19 Bischoff HA, Stahelin HB, Monsch AU, Iverson M, Weyh A, von Dechend M et al Comparison of the Timed “Up and Go” Test in community dwelling and institutionalized elderly women. Age Ageing. 2003; 32: 315-20
    CrossrefPubMedGoogle Scholar
  • 20 Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995; 332: 556-61
    CrossrefPubMedGoogle Scholar
  • 21 Gill TM, Williams CS, Tinetti ME. Assessing risk for the onset of functional dependence among older adults: the role of physical performance. J Am Geriatr Soc. 1995; 43: 603-9
    PubMedGoogle Scholar
  • 22 Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporosis Int. 1993; 3: 7-12
    CrossrefPubMedGoogle Scholar
  • 23 Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW et al AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9 (6) 544-64
    PubMedGoogle Scholar
  • 24 Russell RG, Watts NB, Ebetineo FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733-59
    CrossrefPubMedGoogle Scholar
  • 25 Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19: 80-100
    CrossrefPubMedGoogle Scholar
  • 26 Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999; 25: 97-106
    CrossrefPubMedGoogle Scholar
  • 27 Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A et al Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone. 2003; 33: 132-43
    CrossrefPubMedGoogle Scholar
  • 28 Wong M, Lord S, Lu Y, Lakshmanan M, Scheele W. Raloxifene does not affect neuromuscular related risk factors for falling or the incidence of falls in postmenopausal women with osteoporosis. J Am Geriatr Soc. 2000; 48: S44 (P134)
    PubMedGoogle Scholar
  • 29 Ringe JD. Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence. 2010; 4: 231-45
    PubMedGoogle Scholar
  • 30 McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al Effect of Risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001; 344: 333-40
    CrossrefPubMedGoogle Scholar
  • 31 Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L et al Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fractures: the FLEX trial. J Bone Mineral Res. 2010; 25 (5) 976-82
    CrossrefPubMedGoogle Scholar
  • 32 Dollery C. editor. Alfacalcidol – therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999: A75-79
  • 33 Ikeda K, Ogata E. The effect of vitamin D on osteoblasts and osteoclasts. Curr Opin Orthop. 1999; 10: 339-43
    CrossrefPubMedGoogle Scholar
  • 34 Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N et al Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct action from estrogen. J Bone Mineral Res. 2000; 15: 770-4
    PubMedGoogle Scholar
  • 35 Francis RM, Boyle IT, Moniz C, Sucliffe AM, Davis BS, Benstall GH et al A comparison of the effects of alfacalcidol treatment and vitamin D supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int. 1996; 6: 284-90
    PubMedGoogle Scholar
  • 36 Erben R. G. Vitamin D analogs and bone. J Musculoskel Neuronal Interact. 2001; 2 (l) 59-69
    PubMedGoogle Scholar
  • 37 Carswell S. Vitamin D in the nervous system: actions and therapeutic potential. In: Feldman D, Glorieux FH, Pike JW, editors. Vitamin D. Chapter 71. San Diego: Academic Press; 1997: 1197-1211
    Google Scholar
  • 38 Koike T, Okawa T, Wada M, Kita T, Takaoka K. Effects of a long-term alfacalcidol or calcitonin administration on body sway in Japanese elderly women. J Bone Miner Res. 2003; 8 (Suppl 2) S168
    PubMedGoogle Scholar
  • 39 Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N et al Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002; 23: 560-9
    CrossrefPubMedGoogle Scholar
  • 40 Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005; 76: 176-86
    CrossrefPubMedGoogle Scholar
  • 41 O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Mineral Metab. 2008; 26: 531-42
    CrossrefPubMedGoogle Scholar
  • 42 Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H. Curative effect of combined treatment with alendronate and l∞-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol. 2002; 89: 255-66
    CrossrefPubMedGoogle Scholar
  • 43 Saito M, Shiraishi A, Ito M, Sakai S, Hayakawa N, Mihara M et al Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen crosslinks of callus in the fracture repair rat model. Bone. 2010; 46: 1170-9 doi: 10.1016/j.bone.2009.12.008
    CrossrefPubMedGoogle Scholar
  • 44 Reszka AA, Pun S, Rodan GA, Freedman LP, Kimmel DB. Bone Anabolic effects of 1,25(OH)2 vitamin D3 are detected only in the presence of a powerful antiresorptive. J Bone Miner Res. 2004; 19: S483
    PubMedGoogle Scholar
  • 45 Frediani B, Allegri A, Bisogno S, Marcolongo R. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in post-menopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest. 1998; 15: 235-44
    CrossrefPubMedGoogle Scholar
  • 46 Ones K, Schacht E, Dukas L, Caglar N. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Int J Epidemiol. 2007; 4 (1)
    PubMedGoogle Scholar
  • 47 Gaal J, Bender T, Varga J, Horvath I, Kiss J, Somogyi P et al Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study. Rheumatol Int. 2009; 30 (1) 25-31 doi: 10.1007/s00296-009-0892-9
    CrossrefPubMedGoogle Scholar
  • 48 Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-trial). Rheumatol Int. 2007; 27: 425-34
    CrossrefPubMedGoogle Scholar
  • 49 Ringe JD, Schacht E. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int. 2007; 28: 103-11
    CrossrefPubMedGoogle Scholar
  • 50 Felsenberg D, Bock O, Boerst H, Armbrecht G, Beller G, Degner C et al Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. Accepted for publication in J Musculoskelet Neuronal Interact.
    PubMed
  • 51 Orimo H, Nakamura T, Shiraki M, Ohta H, Fukunaga M. Alendronate with alfacalcidol yields greater effectiveness than monotherapy with alendronate in postmenopausal elderly patients with osteoporosis: results from the Joint-02 randomized, controlled trial. Osteopros Int. 2010; 21 (Suppl:) 184
    PubMedGoogle Scholar
  • 52 Frediani B, Allegri A, Storri L, Falsetti P, Bisogno S, Baldi F et al Alendronate plus calcitriol: a combined treatment in corticosteroid induced osteoporosis. Osteoporos Int. 1999; 9: S10-11
    PubMedGoogle Scholar
  • 53 Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L et al Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001; 16: 2111-7
    CrossrefPubMedGoogle Scholar
  • 54 Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int. 2006; 17: 942-9
    CrossrefPubMedGoogle Scholar
  • 55 Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol. 2008; 35: 2249-54
    CrossrefPubMedGoogle Scholar
  • 56 Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2004; 24: 63-70
    CrossrefPubMedGoogle Scholar
  • 57 Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int. 1999; 65: 317-27
    CrossrefPubMedGoogle Scholar
  • 58 Schacht E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neuronal Interact. 2007; 7: 174-84
    PubMedGoogle Scholar
  • 59 Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for osteoporosis, a low creatinine clearance of < 65 ml/min is a risk factor for falls and fractures. Osteoporos Int. 2005; 16: 1683-90
    CrossrefPubMedGoogle Scholar
  • 60 Ringe JD, van der Geest SA, Möller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Drugs Aging. 2006; 23: 569-78
    CrossrefPubMedGoogle Scholar
  • 61 Ringe JD, Fardellone P, Kruse HP, Amling M, van der Geest SA, Möller G. Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies. Drugs Aging. 2009; 26: 241-4
    CrossrefPubMedGoogle Scholar